Training activity information
Details
With supervision from a consultant, interpret the results of appropriate molecular tests, which contribute to the final pathology report for the following pathologies:
- Skin cancer
- Colorectal cancer
- Endometrial cancer
- Breast cancer
- Urological cancer
Type
Developmental training activity (DTA)
Evidence requirements
Evidence the activity has been undertaken by the trainee​.
Reflection on the activity at one or more time points after the event including learning from the activity and/or areas of the trainees practice for development.
An action plan to implement learning and/or to address skills or knowledge gaps identified.
Considerations
- RCPath datasets
- Local SOPs and/or proforma
- NICE guidance
- Cancer screening programme guidance
- Genomic test directory
- Biomarkers
- Implications for patient therapy
- Consider pre-analytical factors in the limitations of the tests (X-ref to indicative content)
Reflective practice guidance
The guidance below is provided to support reflection at different time points, providing you with questions to aid you to reflect for this training activity. They are provided for guidance and should not be considered as a mandatory checklist. Trainees should not be expected to provide answers to each of the guidance questions listed.
Before action
- What types of molecular test results are you likely to encounter for these pathologies?
- Do you understand the basic principles of molecular biology relevant to cancer pathogenesis?
- Are you familiar with how molecular test results are typically reported?
- Do you know the clinical significance of common molecular alterations in the listed cancers (e.g., mutations, amplifications)?
- Do you understand how molecular test results are integrated into the final pathology report and influence clinical decision-making?
- How will this activity improve your ability to interpret complex molecular test reports?
- What will you learn about the correlation between specific molecular findings and pathological features or clinical outcomes?
- How will you develop your skills in communicating the significance of molecular results?
- Review the literature on the molecular pathology of the listed cancers, focusing on the interpretation of key molecular markers.
- Discuss with your training officer specific cases and the interpretation of their molecular test results.
- Consider potential challenges in understanding the clinical implications of certain molecular findings and think about how to address these with your supervisor.
In action
- What specific genetic alterations or biomarkers are you identifying in the results? What is their immediate known significance in these cancers?
- How are you integrating the molecular findings with the histological and immunohistochemical information? Are there any discrepancies?
- What are the immediate implications of these molecular findings for diagnosis, prognosis, or potential treatment strategies?
- Are there any unexpected or ambiguous results? How are you considering these in your interpretation?
On action
- What were the key molecular findings in the test results for each cancer type?
- How were these molecular findings integrated with the histological and immunohistochemical information?
- What were the consultant’s key points in interpreting the clinical significance of these results?
- How did interpreting these molecular results enhance your understanding of the molecular pathology of these cancers?
- What are the implications of these molecular findings for diagnosis, prognosis, and potential treatment strategies?
- Were there any results that were unexpected or difficult to interpret?
- What did you learn from these?
- How important is it to correlate molecular findings with other pathological information?
- What specific molecular alterations will you pay closer attention to in future cases of these cancers?
- What further resources will you use to deepen your understanding of molecular test interpretation?
- How will you approach the integration of molecular results into pathology reports?
Beyond action
- How has your experience interpreting a wider range of molecular tests and understanding their clinical significance changed your perspective on your initial interpretations in this DTA?
- Reflecting on cases where molecular biomarker tests informed diagnostic and prognostic patient stratification and targeted therapies, how has this broadened context influenced your understanding of the importance of accurate interpretation in this DTA?
- How has this activity built a foundation for your ability to discuss the role of genomics and molecular results in cancer diagnosis and prognosis?
- Have you since encountered discrepancies or challenges in molecular test interpretation that have caused you to re-evaluate your initial understanding gained from this DTA?
Relevant learning outcomes
| # | Outcome |
|---|---|
| # 2 |
Outcome
Interpret immunohistochemistry and molecular tests applied to malignant pathologies. |